The global nasal allergy treatment market enjoys a valuation of US$ 6.6 Billion in 2022, and it is further projected to expand at a CAGR of 6.7% over the forecasted years. According to a recent study by Future Market Insights, allergic rhinitis by disease is leading the market with a share of about 65.8% in the year 2022, within the global market.
Market Outlook
| Data Points | Market Insights |
|---|---|
| Market Value 2022 | US$ 6.6 Billion |
| Market Value 2033 | US$ 13.3 Billion |
| CAGR 2023 to 2033 | 6.7% |
| Market Share of Top 5 Countries | 62.1% |
| Key Market Players | Merck KGaA, Johnson & Johnson, Allergopharma, Sanofi SA, McNeil Consumer Healthcare, Genentech Inc., GlaxoSmithKline PLC, Leti Pharma, Alerpharma S.A, Allergan, Inc., Meda Pharmaceuticals, Inc, Novartis International AG, Bausch Health Companies Inc., Allergopharma , ALK Abello, Stallergenes, Greer, Allergy Therapeutics, Aimmune Therapeutics, Biomay AG, HAL Allergy Group, Bayer, AstraZeneca |
Nasal allergy, or allergic rhinitis (AR), a non-infectious inflammatory disease of the nasal mucosa following exposure to inhaled allergens in atopic patients, is mediated by IgE and involves a number of immune cells and cytokines. The currently available treatment options have increased due to a growing number of manufacturers identifying allergy as an area of interest and also with the help of a research and development team they are bringing in new innovative treatment and therapy options to the market. Although we are in the second wave of allergic diseases there is still a persistent amount of the population who suffer from nasal allergies.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The global sales of the market are anticipated to rise at a CAGR of 6.7% between 2023 and 2033, owing to the rising prevalence of allergic diseases.
The global market holds around 32.6% share of the overall global allergy treatment market with a value of around US$ 20.2 Billion, in 2022.
The market is expanding as a result increase in the patient pool suffering from allergies. In fact, it is anticipated that the need for nasal allergy treatments would rise in the coming years due to the patient’s comfort and ease as it reduces inflammation, and remove congestion. The incidence rate and prevalence rate of allergic rhinitis are growing rapidly owing to which the demand for available treatments is expected to increase over the forecast period.
Some of the most popular therapies for nasal allergies are antihistamines, decongestants, nasal corticosteroids, allergen immunotherapy, and leukotriene receptor antagonists. Antihistamines rule the market, as it is one of the highly prescribed and adopted drugs for the treatment of allergies with or without prescription.
Owing to the above-mentioned factors, the global market is expected to grow at a prominent pace, and reach a valuation of around US$ 13.3 billion during the year 2033.
Globally, the prevalence of hay fever/allergic rhinitis was registered at ~35%, which is gaining the attraction of manufacturers to develop a specific treatment for this indication. This creates an enormous opportunity for the manufacturer to explore the nasal allergy treatment market. The life science industry has set foot into the pharmaceutical industry giving rise to multiple biopharma companies that have proven technology and advanced treatment options that are exclusive and received approval, this gives healthcare specialists to rely upon these new treatment options.
For instance, the main method for treating people with sensitivities to aeroallergens is subcutaneous immunotherapy (SCIT). Subcutaneous immunotherapy (SCIT), a revolutionary treatment for allergic illnesses, reduces discomfort while modifying allergic disease by concentrating on the underlying immunological mechanism. In numerous well-controlled clinical trials, its effectiveness and safety have been proven in the treatment of allergies, allergic rhinitis/rhinoconjunctivitis, asthma, and hypersensitivity to stinging insects.
Overall, it is anticipated that the market for nasal allergy treatments will rise over the coming years as more research and development are put into creating fresh, efficient treatment choices.
Principal Consultant
The market is experiencing a decline due to the adverse effects associated with allergy shots and tablets.
Along with that, patients can experience minor effects such as redness or swelling at the injection site or effects on the entire body or particular body system. Along with that, rarely, a serious systemic reaction called anaphylaxis can develop.
In a few cases, people can experience systematic reactions such as hives, nasal congestion, watery eyes, and sneezing. More severe reactions may include wheezing or chest tightness and throat swelling. Rarely, allergy treatments can cause anaphylaxis, a potentially fatal reaction. It may result in low blood pressure and respiratory difficulties. An allergy shot can sometimes cause a significant reaction in a person. The majority of these can happen within 30 minutes of the injection.
The side effects associated with the treatment may hinder the market growth.
The USA dominates the North American region with a total market share of around 92.4% in 2022 and is expected to continue to maintain consistent growth over the entire projected period with a CAGR of 5.8%. The main drivers of nasal allergy prevalence in the United States include environmental factors such as air pollution, climate change, and exposure to allergens such as pollen and dust mites.
Allergies are the sixth most common chronic ailment in the United States, according to the American College of Allergy, Asthma & Immunology, with a cost of more than $18 billion annually. Each year, more than 50 million Americans experience allergic reactions. The frequency of AR was 19.9%, according to a recent large retrospective cohort study by Frontiers Media S.A. in the year 2023. According to the National Health Interview Survey done by the Centers for Disease Control and Prevention in 2018, 19.2 million adults in the US had hay fever (allergic rhinitis) in the previous 12 months.
Since the prevalence is high the manufacturer finds it lucrative to regulate in such a market, therefore this factor influences the nasal allergy treatment market in the most favorable manner in the USA market.
China has a market share of 65.8% in the East Asia nasal allergy treatment market in 2022. Disease progression can be retarded by taking precautions such as diagnostic tests which include the provocation test, specific IgG4 test, tIgE test, and multiple other specific tests that can lead to successful treatment outcomes. China is focusing on improving its diagnosis to pace up into the global market.
For the prevention and treatment of allergic disorders, allergen detection is essential. Although China's technology is now lacking, many of the diagnostic gaps will soon be filled thanks to the development of new microparticle- and array-based methods.
To assist allergists and laboratory personnel in improving the diagnostic standard and directing the treatment of allergic illnesses for the benefit of patients and the market as a whole, this consensus summarizes the existing in vivo and in vitro diagnostic procedures for allergens.
Germany holds a market share of 29.8% in 2022 in the European nasal allergy treatment market, owing to the presence of many established players in European countries.
Bencard Allergie, the German division of Allergy Therapeutics in the United Kingdom, which creates allergy vaccinations, was referenced by Labiotech UG in June 2022. The first allergoids for allergen-specific immunotherapies were marketed by a German business. With the use of virus-like particles, Allergy Therapeutics, and its affiliates are developing a novel method for allergy immunotherapy. Bencard appears to be in a strong position despite its opponents. According to a recent report from Allergy Therapeutics, Bencard contributes 60% of the company's revenues in Germany, which is where sales are growing the fastest.
Germany is strengthening its manufacturing and development of novel drugs which will positively grow the market in the future.
India holds a share of around 48.6% in the South Asia market in 2022.
India has one of the highest levels of pollution, which is largely brought on by the use of mosquito coils and incense sticks indoors, and by outdoor, biomass, fossil fuels, and vehicle exhausts. According to Elsevier Inc., there are an estimated 37.5 million instances of asthma in India, and recent studies have indicated that the frequency of allergic rhinitis and asthma would rise in 2020.
Although India's prevalence rates are generally lower than those of high-income nations, there are still several million instances of the disease overall, according to various estimates. Indian manufacturers must therefore increase their supply of treatment drugs in order to handle such a sizable patient population.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Allergic rhinitis is expected to give high growth at a CAGR of 6.4% between 2023 and 2033. As per American Academy of Allergy Asthma and Immunology, 2022, allergic rhinitis affects almost 10-30% of the population worldwide. Additionally, sensitization to foreign proteins present in the environment affects upto 40% of the global population. In the geriatric population, rhinitis is less commonly allergic in nature. Hence the prevalence contributes to the global shares.
Tablets/Capsules are mostly favored by patients suffering from allergies. It has a market share of 37.1% in the global market in 2022.
The most popular sort of pill is a tablet. They encourage market growth since they are an affordable, secure, and efficient method of delivering oral medications. Tablets and capsules are frequently used by makers and formulators of drug products as a dosage form that is affordable.
OTC has a market share of 76.3% in the global market in 2022. OTC medications are easier for customers to obtain because they are readily available and may be bought without a prescription. People aren't obliged to wait for medications to be filled or schedule appointments with doctors, which saves time and money. Because OTC drugs are typically less expensive than prescription drugs, more people can afford them.
Oral route of administration is mostly preferred by patients. It has a market share of 36.6% in the global market in 2022.
Patients can take oral medications at home without the need for medical supervision because they are simple to administer. Patients who need long-term treatment for chronic diseases would especially benefit from this. Drugs used orally are frequently less expensive than medications taken orally or intravenously, which require more specialized equipment and medical supervision.
Antihistamines have a market share of 46.0% in the global market in 2022. Since histamine, a substance secreted by the body in response to an allergen is blocked by antihistamines, they are frequently given for allergies. Sneezing, itching, and runny nose are examples of common allergic reaction symptoms that are brought on by histamine. A variety of allergic reactions, including as hay fever, allergic rhinitis, and hives, can be successfully treated with them.
Hospital pharmacies hold a market share of 35.9% during the year 2022. The main locations where easily accessible licensed and approved medicine is found are hospitals. Hospital pharmacies may greatly enhance patient care by working together with doctors, nurses, and pharmacy teams to supply the appropriate medications and supplies in accordance with treatment procedures. The assurance of better patient outcomes aids hospitals in exceeding patient satisfaction targets. The segment is anticipated to grow at a profitable pace over the forecast period because of the comprehensive care provided in hospital settings.
Increase in number of pipeline products and approval by the regulatory bodies, along with merger and acquisition by key players in different regions, are key differentiating strategies that nasal allergy treatment manufacturers are adopting.
Similarly, recent developments related to companies manufacturing nasal allergy treatment drugs have been tracked by the team at Future Market Insights. These are available in the full report.
| Attribute | Details |
|---|---|
| Forecast Period | 2018 to 2022 |
| Historical Data Available for | 2023 to 2033 |
| Market Analysis | US$ Million for Value |
| Key Regions Covered | North America, Latin America, Europe, South Asia, East Asia, Oceania, and the Middle East & Africa |
| Key Countries Covered | The USA, Canada, Brazil, Mexico, Argentina, the United kingdom, Germany, Italy, Russia, Spain, France, Benelux, India, Thailand, Indonesia, Malaysia, Japan, China, South Korea, Australia, New Zealand, Türkiye, GCC Countries, North Africa and South Africa |
| Key Market Segments Covered | Disease Type, Form, Prescription Type, Route of Administration, Treatment, Distribution Channel and Region |
| Key Companies Profiled |
|
| Report Coverage | Market Forecast, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, Strategic Growth Initiatives |
| Pricing | Available upon Request |
The growth potential of the power nibbler market is 6.7% through 2033.
Adverse effect of tablets is likely to limit market growth.
North America is likely to capture a CAGR of 5.8% in 2023.
The United States is estimated as the fastest-growing country.
Allergic rhinitis segment is leading the global market in 2023.
1. Executive Summary | Nasal Allergy Treatment Market
1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply-Side Trends
1.4. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
2.3. Inclusions and Exclusions
3. Key Market Trends
3.1. Key Trends Impacting the Market
3.2. Product Innovation / Development Trends
4. Value Added Insights
4.1. Disease Epidemiology
4.1.1. Prevalence Population
4.1.2. Diagnosed Prevalence Cases
4.1.3. Gender Specific Cases
4.1.4. Severity Specific Cases
4.2. Annual Patient Volume of Disease Type for Key Countries
4.3. Regulatory Landscape
4.4. Patient Pool Suffering from Allergy
4.5. Patient Treatment Journey
4.6. Pipeline Assessment
4.7. PESTLE Analysis
4.8. Porter’s Analysis
5. Market Background
5.1. Macro-Economic Factors
5.1.1. Global GDP Growth Outlook
5.1.2. Global Healthcare Expenditure Outlook
5.1.3. Global Life Expectancy Outlook
5.1.4. Pharmaceutical Spending
5.1.5. Global Allergy Treatment Market Outlook
5.2. Forecast Factors - Relevance & Impact
5.2.1. Increase Prevalence of Allergy Rhinitis
5.2.2. Diagnostic Rate (%)
5.2.3. Treatment Seeking Rate (%)
5.2.4. Cases treated with Nasal Allergies
5.2.5. Overall Cost of Treatment
5.2.6. Recent Advancements In Technology
5.2.7. Regulatory Framework
5.2.8. Key Strategic Developments By Market Players
5.2.9. Adverse Effects May Impact the Market Growth
5.2.10. Growing Investment in Healthcare Sector
5.3. Market Dynamics
5.3.1. Drivers
5.3.2. Restraints
5.3.3. Opportunity
6. COVID-19 Crisis – Impact Assessment
6.1. COVID-19 and Impact Analysis
6.1.1. Revenue By Disease Type
6.1.2. Revenue By Form
6.1.3. Revenue By Prescription Type
6.1.4. Revenue By Route of Administration
6.1.5. Revenue By Treatment
6.1.6. Revenue By Distribution Channel
6.1.7. Revenue By Country
6.2. 2022 Market Scenario
7. Global Market Demand (in Value or Size in US$ Million) Analysis 2018 to 2022 and Forecast, 2023 to 2033
7.1. Historical Market Value (US$ Million) Analysis, 2018 to 2022
7.2. Current and Future Market Value (US$ Million) Projections, 2023 to 2033
7.2.1. Y-o-Y Growth Trend Analysis
7.2.2. Absolute $ Opportunity Analysis
8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Disease Type
8.1. Introduction / Key Findings
8.2. Historical Market Size (US$ Million) Analysis, By Disease Type, 2018 to 2022
8.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Disease Type, 2023 to 2033
8.3.1. Allergic Rhinitis
8.3.2. Seasonal Allergic Rhinitis
8.3.3. Perennial Allergic Rhinitis
8.3.4. Non-Allergic Rhinitis
8.3.5. Infectious Rhinitis
8.4. Market Attractiveness Analysis By Disease Type
9. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Form
9.1. Introduction / Key Findings
9.2. Historical Market Size (US$ Million) Analysis, By Form, 2018 to 2022
9.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Form, 2023 to 2033
9.3.1. Tablets/Capsules
9.3.2. Liquid
9.3.3. Creams & Lotions
9.3.4. Drops
9.3.5. Spray
9.4. Market Attractiveness Analysis By Form
10. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Prescription Type
10.1. Introduction / Key Findings
10.2. Historical Market Size (US$ Million) Analysis, By Prescription Type, 2018 to 2022
10.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Prescription Type, 2023 to 2033
10.3.1. OTC
10.3.2. Prescription based
10.4. Market Attractiveness Analysis By Prescription Type
11. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Route of Administration
11.1. Introduction / Key Findings
11.2. Historical Market Size (US$ Million) Analysis, By Route of Administration, 2018 to 2022
11.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Route of Administration, 2023 to 2033
11.3.1. Oral
11.3.2. Intranasal
11.3.3. Sublingual
11.3.4. Sub Cutaneous
11.3.5. Intravenous
11.4. Market Attractiveness Analysis By Route of Administration
12. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Treatment
12.1. Introduction / Key Findings
12.2. Historical Market Size (US$ Million) Analysis, By Treatment, 2018 to 2022
12.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Treatment, 2023 to 2033
12.3.1. Antihistamines
12.3.2. Decongestants
12.3.3. Nasal Corticosteroids
12.3.4. Allergen Immunotherapy
12.3.5. LeUnited kingdomotriene Receptor Antagonists
12.4. Market Attractiveness Analysis By Treatment
13. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel
13.1. Introduction / Key Findings
13.2. Historical Market Size (US$ Million) Analysis, By Distribution Channel, 2018 to 2022
13.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Distribution Channel, 2023 to 2033
13.3.1. Hospital Pharmacies
13.3.2. Supermarkets/Hypermarkets
13.3.3. Online Pharmacies
13.3.4. Retail Pharmacies
13.3.5. Specialty Clinics
13.3.6. Others
13.4. Market Attractiveness Analysis By Distribution Channel
14. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
14.1. Introduction
14.2. Historical Market Size (US$ Million) Analysis By Region, 2018 to 2022
14.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Region, 2023 to 2033
14.3.1. North America
14.3.2. Latin America
14.3.3. Europe
14.3.4. East Asia
14.3.5. South Asia
14.3.6. Oceania
14.3.7. Middle East and Africa (MEA)
14.4. Market Attractiveness Analysis By Region
15. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033
15.1. Introduction
15.2. Historical Market Size (US$ Million) Trend Analysis by Market Taxonomy, 2018 to 2022
15.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033
15.3.1. By Country
15.3.1.1. USA
15.3.1.2. Canada
15.3.2. By Disease Type
15.3.3. By Form
15.3.4. By Prescription Type
15.3.5. By Route of Administration
15.3.6. By Treatment
15.3.7. By Distribution Channel
15.4. Market Attractiveness Analysis
15.4.1. By Country
15.4.2. By Disease Type
15.4.3. By Form
15.4.4. By Prescription Type
15.4.5. By Route of Administration
15.4.6. By Treatment
15.4.7. By Distribution Channel
15.5. Market Trends
15.6. Key Market Participants - Intensity Mapping
15.7. Drivers and Restraints - Impact Analysis
15.8. Country Level Analysis & Forecast
15.8.1. USA Market Analysis
15.8.1.1. Introduction
15.8.1.2. Market Analysis and Forecast by Market Taxonomy
15.8.1.2.1. By Disease Type
15.8.1.2.2. By Form
15.8.1.2.3. By Prescription Type
15.8.1.2.4. By Route of Administration
15.8.1.2.5. By Treatment
15.8.1.2.6. By Distribution Channel
15.8.2. Canada Market Analysis
15.8.2.1. Introduction
15.8.2.2. Market Analysis and Forecast by Market Taxonomy
15.8.2.2.1. By Disease Type
15.8.2.2.2. By Form
15.8.2.2.3. By Prescription Type
15.8.2.2.4. By Route of Administration
15.8.2.2.5. By Treatment
15.8.2.2.6. By Distribution Channel
16. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033
16.1. Introduction
16.2. Historical Market Size (US$ Million) Trend Analysis by Market Taxonomy, 2018 to 2022
16.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033
16.3.1. By Country
16.3.1.1. Mexico
16.3.1.2. Brazil
16.3.1.3. Argentina
16.3.1.4. Rest of Latin America
16.3.2. By Disease Type
16.3.3. By Form
16.3.4. By Prescription Type
16.3.5. By Route of Administration
16.3.6. By Treatment
16.3.7. By Distribution Channel
16.4. Market Attractiveness Analysis
16.4.1. By Country
16.4.2. By Disease Type
16.4.3. By Form
16.4.4. By Prescription Type
16.4.5. By Route of Administration
16.4.6. By Treatment
16.4.7. By Distribution Channel
16.5. Market Trends
16.6. Key Market Participants - Intensity Mapping
16.7. Drivers and Restraints - Impact Analysis
16.8. Country Level Analysis & Forecast
16.8.1. Mexico Market Analysis
16.8.1.1. Introduction
16.8.1.2. Market Analysis and Forecast by Market Taxonomy
16.8.1.2.1. By Disease Type
16.8.1.2.2. By Form
16.8.1.2.3. By Prescription Type
16.8.1.2.4. By Route of Administration
16.8.1.2.5. By Treatment
16.8.1.2.6. By Distribution Channel
16.8.2. Brazil Market Analysis
16.8.2.1. Introduction
16.8.2.2. Market Analysis and Forecast by Market Taxonomy
16.8.2.2.1. By Disease Type
16.8.2.2.2. By Form
16.8.2.2.3. By Prescription Type
16.8.2.2.4. By Route of Administration
16.8.2.2.5. By Treatment
16.8.2.2.6. By Distribution Channel
16.8.3. Argentina Market Analysis
16.8.3.1. Introduction
16.8.3.2. Market Analysis and Forecast by Market Taxonomy
16.8.3.2.1. By Disease Type
16.8.3.2.2. By Form
16.8.3.2.3. By Prescription Type
16.8.3.2.4. By Route of Administration
16.8.3.2.5. By Treatment
16.8.3.2.6. By Distribution Channel
17. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033
17.1. Introduction
17.2. Historical Market Size (US$ Million) Trend Analysis by Market Taxonomy, 2018 to 2022
17.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033
17.3.1. By Country
17.3.1.1. United kingdom
17.3.1.2. Germany
17.3.1.3. France
17.3.1.4. Italy
17.3.1.5. Spain
17.3.1.6. BENELUX
17.3.1.7. Russia
17.3.1.8. Nordics
17.3.1.9. Rest of Europe
17.3.2. By Disease Type
17.3.3. By Form
17.3.4. By Prescription Type
17.3.5. By Route of Administration
17.3.6. By Treatment
17.3.7. By Distribution Channel
17.4. Market Attractiveness Analysis
17.4.1. By Country
17.4.2. By Disease Type
17.4.3. By Form
17.4.4. By Prescription Type
17.4.5. By Route of Administration
17.4.6. By Treatment
17.4.7. By Distribution Channel
17.5. Market Trends
17.6. Key Market Participants - Intensity Mapping
17.7. Drivers and Restraints - Impact Analysis
17.8. Country Level Analysis & Forecast
17.8.1. U.K. Market Analysis
17.8.1.1. Introduction
17.8.1.2. Market Analysis and Forecast by Market Taxonomy
17.8.1.2.1. By Disease Type
17.8.1.2.2. By Form
17.8.1.2.3. By Prescription Type
17.8.1.2.4. By Route of Administration
17.8.1.2.5. By Treatment
17.8.1.2.6. By Distribution Channel
17.8.2. Germany Market Analysis
17.8.2.1. Introduction
17.8.2.2. Market Analysis and Forecast by Market Taxonomy
17.8.2.2.1. By Disease Type
17.8.2.2.2. By Form
17.8.2.2.3. By Prescription Type
17.8.2.2.4. By Route of Administration
17.8.2.2.5. By Treatment
17.8.2.2.6. By Distribution Channel
17.8.3. France Market Analysis
17.8.3.1. Introduction
17.8.3.2. Market Analysis and Forecast by Market Taxonomy
17.8.3.2.1. By Disease Type
17.8.3.2.2. By Form
17.8.3.2.3. By Prescription Type
17.8.3.2.4. By Route of Administration
17.8.3.2.5. By Treatment
17.8.3.2.6. By Distribution Channel
17.8.4. Italy Market Analysis
17.8.4.1. Introduction
17.8.4.2. Market Analysis and Forecast by Market Taxonomy
17.8.4.2.1. By Disease Type
17.8.4.2.2. By Form
17.8.4.2.3. By Prescription Type
17.8.4.2.4. By Route of Administration
17.8.4.2.5. By Treatment
17.8.4.2.6. By Distribution Channel
17.8.5. Spain Market Analysis
17.8.5.1. Introduction
17.8.5.2. Market Analysis and Forecast by Market Taxonomy
17.8.5.2.1. By Disease Type
17.8.5.2.2. By Form
17.8.5.2.3. By Prescription Type
17.8.5.2.4. By Route of Administration
17.8.5.2.5. By Treatment
17.8.5.2.6. By Distribution Channel
17.8.6. BENELUX Market Analysis
17.8.6.1. Introduction
17.8.6.2. Market Analysis and Forecast by Market Taxonomy
17.8.6.2.1. By Disease Type
17.8.6.2.2. By Form
17.8.6.2.3. By Prescription Type
17.8.6.2.4. By Route of Administration
17.8.6.2.5. By Treatment
17.8.6.2.6. By Distribution Channel
17.8.7. Russia Market Analysis
17.8.7.1. Introduction
17.8.7.2. Market Analysis and Forecast by Market Taxonomy
17.8.7.2.1. By Disease Type
17.8.7.2.2. By Form
17.8.7.2.3. By Prescription Type
17.8.7.2.4. By Route of Administration
17.8.7.2.5. By Treatment
17.8.7.2.6. By Distribution Channel
17.8.8. Nordics Market Analysis
17.8.8.1. Introduction
17.8.8.2. Market Analysis and Forecast by Market Taxonomy
17.8.8.2.1. By Disease Type
17.8.8.2.2. By Form
17.8.8.2.3. By Prescription Type
17.8.8.2.4. By Route of Administration
17.8.8.2.5. By Treatment
17.8.8.2.6. By Distribution Channel
18. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033
18.1. Introduction
18.2. Historical Market Size (US$ Million) Trend Analysis by Market Taxonomy, 2018 to 2022
18.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033
18.3.1. By Country
18.3.1.1. China
18.3.1.2. Japan
18.3.1.3. South Korea
18.3.2. By Disease Type
18.3.3. By Form
18.3.4. By Prescription Type
18.3.5. By Route of Administration
18.3.6. By Treatment
18.3.7. By Distribution Channel
18.4. Market Attractiveness Analysis
18.4.1. By Country
18.4.2. By Disease Type
18.4.3. By Form
18.4.4. By Prescription Type
18.4.5. By Route of Administration
18.4.6. By Treatment
18.4.7. By Distribution Channel
18.5. Market Trends
18.6. Key Market Participants - Intensity Mapping
18.7. Drivers and Restraints - Impact Analysis
18.8. Country Level Analysis & Forecast
18.8.1. China Market Analysis
18.8.1.1. Introduction
18.8.1.2. Market Analysis and Forecast by Market Taxonomy
18.8.1.2.1. By Disease Type
18.8.1.2.2. By Form
18.8.1.2.3. By Prescription Type
18.8.1.2.4. By Route of Administration
18.8.1.2.5. By Treatment
18.8.1.2.6. By Distribution Channel
18.8.2. Japan Market Analysis
18.8.2.1. Introduction
18.8.2.2. Market Analysis and Forecast by Market Taxonomy
18.8.2.2.1. By Disease Type
18.8.2.2.2. By Form
18.8.2.2.3. By Prescription Type
18.8.2.2.4. By Route of Administration
18.8.2.2.5. By Treatment
18.8.2.2.6. By Distribution Channel
18.8.3. South Korea Market Analysis
18.8.3.1. Introduction
18.8.3.2. Market Analysis and Forecast by Market Taxonomy
18.8.3.2.1. By Disease Type
18.8.3.2.2. By Form
18.8.3.2.3. By Prescription Type
18.8.3.2.4. By Route of Administration
18.8.3.2.5. By Treatment
18.8.3.2.6. By Distribution Channel
19. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033
19.1. Introduction
19.2. Historical Market Size (US$ Million) Trend Analysis by Market Taxonomy, 2018 to 2022
19.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033
19.3.1. By Country
19.3.1.1. India
19.3.1.2. Malaysia
19.3.1.3. Thailand
19.3.1.4. Indonesia
19.3.1.5. Philippines
19.3.1.6. Vietnam
19.3.1.7. Rest of South Asia
19.3.2. By Disease Type
19.3.3. By Form
19.3.4. By Prescription Type
19.3.5. By Route of Administration
19.3.6. By Treatment
19.3.7. By Distribution Channel
19.4. Market Attractiveness Analysis
19.4.1. By Country
19.4.2. By Disease Type
19.4.3. By Form
19.4.4. By Prescription Type
19.4.5. By Route of Administration
19.4.6. By Treatment
19.4.7. By Distribution Channel
19.5. Market Trends
19.6. Key Market Participants - Intensity Mapping
19.7. Drivers and Restraints - Impact Analysis
19.8. Country Level Analysis & Forecast
19.8.1. India Market Analysis
19.8.1.1. Introduction
19.8.1.2. Market Analysis and Forecast by Market Taxonomy
19.8.1.2.1. By Disease Type
19.8.1.2.2. By Form
19.8.1.2.3. By Prescription Type
19.8.1.2.4. By Route of Administration
19.8.1.2.5. By Treatment
19.8.1.2.6. By Distribution Channel
19.8.2. Malaysia Market Analysis
19.8.2.1. Introduction
19.8.2.2. Market Analysis and Forecast by Market Taxonomy
19.8.2.2.1. By Disease Type
19.8.2.2.2. By Form
19.8.2.2.3. By Prescription Type
19.8.2.2.4. By Route of Administration
19.8.2.2.5. By Treatment
19.8.2.2.6. By Distribution Channel
19.8.3. Thailand Market Analysis
19.8.3.1. Introduction
19.8.3.2. Market Analysis and Forecast by Market Taxonomy
19.8.3.2.1. By Disease Type
19.8.3.2.2. By Form
19.8.3.2.3. By Prescription Type
19.8.3.2.4. By Route of Administration
19.8.3.2.5. By Treatment
19.8.3.2.6. By Distribution Channel
19.8.4. Indonesia Market Analysis
19.8.4.1. Introduction
19.8.4.2. Market Analysis and Forecast by Market Taxonomy
19.8.4.2.1. By Disease Type
19.8.4.2.2. By Form
19.8.4.2.3. By Prescription Type
19.8.4.2.4. By Route of Administration
19.8.4.2.5. By Treatment
19.8.4.2.6. By Distribution Channel
19.8.5. Philippines Market Analysis
19.8.5.1. Introduction
19.8.5.2. Market Analysis and Forecast by Market Taxonomy
19.8.5.2.1. By Disease Type
19.8.5.2.2. By Form
19.8.5.2.3. By Prescription Type
19.8.5.2.4. By Route of Administration
19.8.5.2.5. By Treatment
19.8.5.2.6. By Distribution Channel
19.8.6. Vietnam Market Analysis
19.8.6.1. Introduction
19.8.6.2. Market Analysis and Forecast by Market Taxonomy
19.8.6.2.1. By Disease Type
19.8.6.2.2. By Form
19.8.6.2.3. By Prescription Type
19.8.6.2.4. By Route of Administration
19.8.6.2.5. By Treatment
19.8.6.2.6. By Distribution Channel
20. Oceania Market 2018 to 2022 and Forecast 2023 to 2033
20.1. Introduction
20.2. Historical Market Size (US$ Million) Trend Analysis by Market Taxonomy, 2018 to 2022
20.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033
20.3.1. By Country
20.3.1.1. Australia
20.3.1.2. New Zealand
20.3.2. By Disease Type
20.3.3. By Form
20.3.4. By Prescription Type
20.3.5. By Route of Administration
20.3.6. By Treatment
20.3.7. By Distribution Channel
20.4. Market Attractiveness Analysis
20.4.1. By Country
20.4.2. By Disease Type
20.4.3. By Form
20.4.4. By Prescription Type
20.4.5. By Route of Administration
20.4.6. By Treatment
20.4.7. By Distribution Channel
20.5. Market Trends
20.6. Key Market Participants - Intensity Mapping
20.7. Drivers and Restraints - Impact Analysis
20.8. Country Level Analysis & Forecast
20.8.1. Australia Market Analysis
20.8.1.1. Introduction
20.8.1.2. Market Analysis and Forecast by Market Taxonomy
20.8.1.2.1. By Disease Type
20.8.1.2.2. By Form
20.8.1.2.3. By Prescription Type
20.8.1.2.4. By Route of Administration
20.8.1.2.5. By Treatment
20.8.1.2.6. By Distribution Channel
20.8.2. New Zealand Market Analysis
20.8.2.1. Introduction
20.8.2.2. Market Analysis and Forecast by Market Taxonomy
20.8.2.2.1. By Disease Type
20.8.2.2.2. By Form
20.8.2.2.3. By Prescription Type
20.8.2.2.4. By Route of Administration
20.8.2.2.5. By Treatment
20.8.2.2.6. By Distribution Channel
21. Middle East and Africa (MEA) Market Analysis 2018 to 2022 and Forecast 2023 to 2033
21.1. Introduction
21.2. Historical Market Size (US$ Million) Trend Analysis by Market Taxonomy, 2018 to 2022
21.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033
21.3.1. By Country
21.3.1.1. GCC Countries
21.3.1.2. Türkiye
21.3.1.3. South Africa
21.3.1.4. Israel
21.3.1.5. North Africa
21.3.1.6. Rest of Middle East and Africa
21.3.2. By Disease Type
21.3.3. By Form
21.3.4. By Prescription Type
21.3.5. By Route of Administration
21.3.6. By Treatment
21.3.7. By Distribution Channel
21.4. Market Attractiveness Analysis
21.4.1. By Country
21.4.2. By Disease Type
21.4.3. By Form
21.4.4. By Prescription Type
21.4.5. By Route of Administration
21.4.6. By Treatment
21.4.7. By Distribution Channel
21.5. Market Trends
21.6. Key Market Participants - Intensity Mapping
21.7. Drivers and Restraints - Impact Analysis
21.8. Country Level Analysis & Forecast
21.8.1. GCC Countries Market Analysis
21.8.1.1. Introduction
21.8.1.2. Market Analysis and Forecast by Market Taxonomy
21.8.1.2.1. By Disease Type
21.8.1.2.2. By Form
21.8.1.2.3. By Prescription Type
21.8.1.2.4. By Route of Administration
21.8.1.2.5. By Treatment
21.8.1.2.6. By Distribution Channel
21.8.2. Türkiye Market Analysis
21.8.2.1. Introduction
21.8.2.2. Market Analysis and Forecast by Market Taxonomy
21.8.2.2.1. By Disease Type
21.8.2.2.2. By Form
21.8.2.2.3. By Prescription Type
21.8.2.2.4. By Route of Administration
21.8.2.2.5. By Treatment
21.8.2.2.6. By Distribution Channel
21.8.3. South Africa Market Analysis
21.8.3.1. Introduction
21.8.3.2. Market Analysis and Forecast by Market Taxonomy
21.8.3.2.1. By Disease Type
21.8.3.2.2. By Form
21.8.3.2.3. By Prescription Type
21.8.3.2.4. By Route of Administration
21.8.3.2.5. By Treatment
21.8.3.2.6. By Distribution Channel
21.8.4. Israel Market Analysis
21.8.4.1. Introduction
21.8.4.2. Market Analysis and Forecast by Market Taxonomy
21.8.4.2.1. By Disease Type
21.8.4.2.2. By Form
21.8.4.2.3. By Prescription Type
21.8.4.2.4. By Route of Administration
21.8.4.2.5. By Treatment
21.8.4.2.6. By Distribution Channel
21.8.5. North Africa Market Analysis
21.8.5.1. Introduction
21.8.5.2. Market Analysis and Forecast by Market Taxonomy
21.8.5.2.1. By Disease Type
21.8.5.2.2. By Form
21.8.5.2.3. By Prescription Type
21.8.5.2.4. By Route of Administration
21.8.5.2.5. By Treatment
21.8.5.2.6. By Distribution Channel
22. Market Structure Analysis
22.1. Market Analysis by Tier of Companies
22.2. Market Share Analysis of Top Players
22.3. Market Presence Analysis
23. Competition Analysis
23.1. Competition Dashboard
23.2. Key Development Analysis
23.3. Branding and Promotional Strategies, by Manufacturers
23.4. Competition Deep Dive
23.4.1. Merck KGaA
23.4.1.1. Overview
23.4.1.2. Product Portfolio
23.4.1.3. Key Financials
23.4.1.4. SWOT Analysis
23.4.1.5. Key Developments
23.4.1.6. Sales Footprint
23.4.1.7. Strategy Overview
23.4.1.7.1. Marketing Strategies
23.4.1.7.2. Product Strategies
23.4.1.7.3. Channel Strategies
23.4.2. Johnson & Johnson
23.4.2.1. Overview
23.4.2.2. Product Portfolio
23.4.2.3. Key Financials
23.4.2.4. SWOT Analysis
23.4.2.5. Key Developments
23.4.2.6. Sales Footprint
23.4.2.7. Strategy Overview
23.4.2.7.1. Marketing Strategies
23.4.2.7.2. Product Strategies
23.4.2.7.3. Channel Strategies
23.4.3. Allergopharma
23.4.3.1. Overview
23.4.3.2. Product Portfolio
23.4.3.3. Key Financials
23.4.3.4. SWOT Analysis
23.4.3.5. Key Developments
23.4.3.6. Sales Footprint
23.4.3.7. Strategy Overview
23.4.3.7.1. Marketing Strategies
23.4.3.7.2. Product Strategies
23.4.3.7.3. Channel Strategies
23.4.4. Sanofi SA
23.4.4.1. Overview
23.4.4.2. Product Portfolio
23.4.4.3. Key Financials
23.4.4.4. SWOT Analysis
23.4.4.5. Key Developments
23.4.4.6. Sales Footprint
23.4.4.7. Strategy Overview
23.4.4.7.1. Marketing Strategies
23.4.4.7.2. Product Strategies
23.4.4.7.3. Channel Strategies
23.4.5. McNeil Consumer Healthcare,
23.4.5.1. Overview
23.4.5.2. Product Portfolio
23.4.5.3. Key Financials
23.4.5.4. SWOT Analysis
23.4.5.5. Key Developments
23.4.5.6. Sales Footprint
23.4.5.7. Strategy Overview
23.4.5.7.1. Marketing Strategies
23.4.5.7.2. Product Strategies
23.4.5.7.3. Channel Strategies
23.4.6. Genentech Inc.
23.4.6.1. Overview
23.4.6.2. Product Portfolio
23.4.6.3. Key Financials
23.4.6.4. SWOT Analysis
23.4.6.5. Key Developments
23.4.6.6. Sales Footprint
23.4.6.7. Strategy Overview
23.4.6.7.1. Marketing Strategies
23.4.6.7.2. Product Strategies
23.4.6.7.3. Channel Strategies
23.4.7. GlaxoSmithKline PLC
23.4.7.1. Overview
23.4.7.2. Product Portfolio
23.4.7.3. Key Financials
23.4.7.4. SWOT Analysis
23.4.7.5. Key Developments
23.4.7.6. Sales Footprint
23.4.7.7. Strategy Overview
23.4.7.7.1. Marketing Strategies
23.4.7.7.2. Product Strategies
23.4.7.7.3. Channel Strategies
23.4.8. Leti Pharma,
23.4.8.1. Overview
23.4.8.2. Product Portfolio
23.4.8.3. Key Financials
23.4.8.4. SWOT Analysis
23.4.8.5. Key Developments
23.4.8.6. Sales Footprint
23.4.8.7. Strategy Overview
23.4.8.7.1. Marketing Strategies
23.4.8.7.2. Product Strategies
23.4.8.7.3. Channel Strategies
23.4.9. Alerpharma S.A
23.4.9.1. Overview
23.4.9.2. Product Portfolio
23.4.9.3. Key Financials
23.4.9.4. SWOT Analysis
23.4.9.5. Key Developments
23.4.9.6. Sales Footprint
23.4.9.7. Strategy Overview
23.4.9.7.1. Marketing Strategies
23.4.9.7.2. Product Strategies
23.4.9.7.3. Channel Strategies
23.4.10. Allergan, Inc.
23.4.10.1. Overview
23.4.10.2. Product Portfolio
23.4.10.3. Key Financials
23.4.10.4. SWOT Analysis
23.4.10.5. Key Developments
23.4.10.6. Sales Footprint
23.4.10.7. Strategy Overview
23.4.10.7.1. Marketing Strategies
23.4.10.7.2. Product Strategies
23.4.10.7.3. Channel Strategies
23.4.11. Meda Pharmaceuticals, Inc
23.4.11.1. Overview
23.4.11.2. Product Portfolio
23.4.11.3. Key Financials
23.4.11.4. SWOT Analysis
23.4.11.5. Key Developments
23.4.11.6. Sales Footprint
23.4.11.7. Strategy Overview
23.4.11.7.1. Marketing Strategies
23.4.11.7.2. Product Strategies
23.4.11.7.3. Channel Strategies
23.4.12. Novartis International AG
23.4.12.1. Overview
23.4.12.2. Product Portfolio
23.4.12.3. Key Financials
23.4.12.4. SWOT Analysis
23.4.12.5. Key Developments
23.4.12.6. Sales Footprint
23.4.12.7. Strategy Overview
23.4.12.7.1. Marketing Strategies
23.4.12.7.2. Product Strategies
23.4.12.7.3. Channel Strategies
23.4.13. Bausch Health Companies Inc.
23.4.13.1. Overview
23.4.13.2. Product Portfolio
23.4.13.3. Key Financials
23.4.13.4. SWOT Analysis
23.4.13.5. Key Developments
23.4.13.6. Sales Footprint
23.4.13.7. Strategy Overview
23.4.13.7.1. Marketing Strategies
23.4.13.7.2. Product Strategies
23.4.13.7.3. Channel Strategies
23.4.14. Allergopharma
23.4.14.1. Overview
23.4.14.2. Product Portfolio
23.4.14.3. Key Financials
23.4.14.4. SWOT Analysis
23.4.14.5. Key Developments
23.4.14.6. Sales Footprint
23.4.14.7. Strategy Overview
23.4.14.7.1. Marketing Strategies
23.4.14.7.2. Product Strategies
23.4.14.7.3. Channel Strategies
23.4.15. ALK Abello
23.4.15.1. Overview
23.4.15.2. Product Portfolio
23.4.15.3. Key Financials
23.4.15.4. SWOT Analysis
23.4.15.5. Key Developments
23.4.15.6. Sales Footprint
23.4.15.7. Strategy Overview
23.4.15.7.1. Marketing Strategies
23.4.15.7.2. Product Strategies
23.4.15.7.3. Channel Strategies
23.4.16. Stallergenes Greer
23.4.16.1. Overview
23.4.16.2. Product Portfolio
23.4.16.3. Key Financials
23.4.16.4. SWOT Analysis
23.4.16.5. Key Developments
23.4.16.6. Sales Footprint
23.4.16.7. Strategy Overview
23.4.16.7.1. Marketing Strategies
23.4.16.7.2. Product Strategies
23.4.16.7.3. Channel Strategies
23.4.17. Allergy Therapeutics
23.4.17.1. Overview
23.4.17.2. Product Portfolio
23.4.17.3. Key Financials
23.4.17.4. SWOT Analysis
23.4.17.5. Key Developments
23.4.17.6. Sales Footprint
23.4.17.7. Strategy Overview
23.4.17.7.1. Marketing Strategies
23.4.17.7.2. Product Strategies
23.4.17.7.3. Channel Strategies
23.4.18. Aimmune Therapeutics
23.4.18.1. Overview
23.4.18.2. Product Portfolio
23.4.18.3. Key Financials
23.4.18.4. SWOT Analysis
23.4.18.5. Key Developments
23.4.18.6. Sales Footprint
23.4.18.7. Strategy Overview
23.4.18.7.1. Marketing Strategies
23.4.18.7.2. Product Strategies
23.4.18.7.3. Channel Strategies
23.4.19. Biomay AG
23.4.19.1. Overview
23.4.19.2. Product Portfolio
23.4.19.3. Key Financials
23.4.19.4. SWOT Analysis
23.4.19.5. Key Developments
23.4.19.6. Sales Footprint
23.4.19.7. Strategy Overview
23.4.19.7.1. Marketing Strategies
23.4.19.7.2. Product Strategies
23.4.19.7.3. Channel Strategies
23.4.20. HAL Allergy Group
23.4.20.1. Overview
23.4.20.2. Product Portfolio
23.4.20.3. Key Financials
23.4.20.4. SWOT Analysis
23.4.20.5. Key Developments
23.4.20.6. Sales Footprint
23.4.20.7. Strategy Overview
23.4.20.7.1. Marketing Strategies
23.4.20.7.2. Product Strategies
23.4.20.7.3. Channel Strategies
23.4.21. Bayer
23.4.21.1. Overview
23.4.21.2. Product Portfolio
23.4.21.3. Key Financials
23.4.21.4. SWOT Analysis
23.4.21.5. Key Developments
23.4.21.6. Sales Footprint
23.4.21.7. Strategy Overview
23.4.21.7.1. Marketing Strategies
23.4.21.7.2. Product Strategies
23.4.21.7.3. Channel Strategies
23.4.22. AstraZeneca
23.4.22.1. Overview
23.4.22.2. Product Portfolio
23.4.22.3. Key Financials
23.4.22.4. SWOT Analysis
23.4.22.5. Key Developments
23.4.22.6. Sales Footprint
23.4.22.7. Strategy Overview
23.4.22.7.1. Marketing Strategies
23.4.22.7.2. Product Strategies
23.4.22.7.3. Channel Strategies
24. Assumptions and Acronyms Used
25. Research Methodolog
Explore Healthcare Insights
View Reports
Nasal Allergy Treatment Market
